Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Onconetix Inc. is a cutting-edge biotechnology firm committed to revolutionizing cancer care with its innovative diagnostic and therapeutic solutions. Utilizing a proprietary technology platform, the company specializes in early detection and personalized treatment for a range of malignancies, addressing key unmet needs in the oncology space. With a strong and diverse product pipeline, Onconetix is well-positioned to capitalize on the increasing demand for effective cancer therapies, aiming to significantly improve patient outcomes through its advanced research and development efforts in this dynamic and rapidly advancing field.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$0.84
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 13, 2026 | — | $-1.28 | — | $-1.28 | — | $17.1K | — | 1D Pre-7.9% | On-Day-1.0% | 1D Post-8.1% |
Q ended Mar 31, 2026 Reported May 13, 2026 | $0.00 | $0.00 | Met | $-6.71 | — | $21.5K | — | 1D Pre+1.4% | On-Day-5.1% | 1D Post+0.8% |
Q ended Dec 31, 2025 Reported Mar 12, 2026 | $0.00 | $0.00 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| Met |
| — |
| — |
| $303.6K |
| — |
| 1D Pre+8.0% |
| On-Day-8.4% |
| 1D Post-5.2% |
Q ended Sep 30, 2025 Reported Nov 13, 2025 | $0.00 | $-6.25 | Miss | — | — | $303.7K | — | 1D Pre+0.7% | On-Day-11.3% | 1D Post-6.1% |